[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:extrahepatic-cholangiocarcinoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":40,"states":41},"Extrahepatic Cholangiocarcinoma",5,[7,15,21,28,34],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07265674","A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer",[11],"Phase 3","RECRUITING","2026-08-26T02:19:04.543908Z","2026-05-05T02:43:28.844774Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT07221253","A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)",[11],"2026-08-26T02:17:53.433613Z","2026-05-05T02:43:28.533233Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":26,"content_modified":27},"NCT05285358","Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases",[25],"Phase 1","2026-08-26T02:19:13.549512Z","2026-05-05T02:35:31.605465Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT06101277","Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)",[],"2026-08-26T02:16:24.970704Z","2026-07-05T05:32:16.744017Z",{"nct_id":35,"title":36,"phases":37,"status":12,"updated_at":38,"content_modified":39},"NCT07277413","A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors",[25],"2026-08-26T02:16:01.910993Z","2026-07-05T05:32:16.679197Z",[],[42,45,49,52],{"state":43,"count":5,"slug":44},"California","california",{"state":46,"count":47,"slug":48},"Florida",3,"florida",{"state":50,"count":47,"slug":51},"New York","new-york",{"state":53,"count":47,"slug":54},"Texas","texas"]